Evidence-Based Treatment of Actinic Keratoses in Older Adults

  • Shannon Famenini
  • Nason Azizi
  • Andy Liu
  • Anne Lynn S. ChangEmail author


Actinic keratoses are common in older patient populations and the prevalence increases with age. In this chapter, we review the latest clinical data on actinic keratosis treatment as it relates to older adults, outlining the pros and cons of various therapeutic modalities in this special population.


Actinic keratosis Treatment Elderly Geriatric 


  1. 1.
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Rigel DS, Cockerell CJ, Carucci J, Wharton J. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Bolognia textbook of dermatology. 2nd ed. Spain: Mosby Elsevier; 2008. p. 1645.Google Scholar
  3. 3.
    Werner R, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18.PubMedCrossRefGoogle Scholar
  4. 4.
    Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Ishioka P, Marques SA, Hirai AT, Marques ME, Hirata SH, Yamada S. Prevalence of precancerous skin lesions and non-melanoma skin cancer in Japanese-Brazilians in Bauru, Sao Paulo State, Brazil. Cad Saude Publica. 2009;25:965–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Feldman SR, Fleischer Jr AB, McConnell RC. Most common dermatologic problems identified by internists, 1990–1994. Arch Intern Med. 1998;158:726–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998;139:1033–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Vitasa BC, Taylor HR, Strickland PT, Rosenthal FS, West S, Abbey H, et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer. 1990;65:2811–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372:773–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1147–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Goldberg LH, Kaplan B, Vergilis-Kalner I, Landau J. Liquid nitrogen: temperature control in the treatment of actinic keratosis. Dermatol Surg. 2010;36:1956–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12, Cd004415.PubMedGoogle Scholar
  14. 14.
    Jeffes III EW, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol. 2000;1:167–79.PubMedCrossRefGoogle Scholar
  15. 15.
    Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Poziomczyk CS, Koche B, Dornelles Mde A, Dornelles SI. Pain evaluation in the cryosurgery of actinic keratoses. An Bras Dermatol. 2011;86:645–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970;101:132–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Weinberg JM. Topical therapy for actinic keratoses: current and evolving therapies. Rev Recent Clin Trials. 2006;1:53–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Werschler WP. Considerations for use of Fluorouracil cream 0.5 % for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol. 2008;1:22–7.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70:30–6.PubMedGoogle Scholar
  21. 21.
    Stough D, Bucko AD, Vamvakias G, Rafal ES, Davis SA. Fluorouracil cream 0.5 % for actinic keratoses on multiple body sites: an 18-month open-label study. Cutis. 2010;85:267–73.PubMedGoogle Scholar
  22. 22.
    Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Fluorouracil 5 % and 0.5 % creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis. 2004;74:18–23.PubMedGoogle Scholar
  23. 23.
    Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56 Suppl 1:18–22. discussion 3.PubMedGoogle Scholar
  24. 24.
    Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatolog Treat. 2010;21:267–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990–1000.PubMedCrossRefGoogle Scholar
  26. 26.
    Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200.PubMedCrossRefGoogle Scholar
  27. 27.
    Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, et al. A randomized, double-blind, vehicle-controlled study to assess 5 % imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138:1498–502.PubMedCrossRefGoogle Scholar
  29. 29.
    Strohal R, Kerl H, Schuster L. Treatment of actinic keratoses with 5 % topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists. J Drugs Dermatol. 2012;11:574–8.PubMedGoogle Scholar
  30. 30.
    Tanghetti E, Werschler P. Comparison of 5 % 5-fluorouracil cream and 5 % imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007;6:144–7.PubMedGoogle Scholar
  31. 31.
    Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Hanke CW, Swanson N, Bruce S, Berman B, Kulp J, Levy S. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75 % or 2.5 % cream. J Drugs Dermatol. 2011;10:165–70.PubMedGoogle Scholar
  34. 34.
    Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66:486–93.PubMedCrossRefGoogle Scholar
  36. 36.
    Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68:S39–48.PubMedCrossRefGoogle Scholar
  38. 38.
    Lebwohl M, Shumack S, Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Ericson MB, Wennberg AM, Larko O. Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag. 2008;4:1–9.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56:125–43.PubMedCrossRefGoogle Scholar
  41. 41.
    Jeffes EW, McCullough JL, Weinstein GD, Fergin PE, Nelson JS, Shull TF, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol. 1997;133:727–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Tran DT, Salmon R. Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes. Australas J Dermatol. 2011;52:195–201.PubMedCrossRefGoogle Scholar
  43. 43.
    Sandberg C, Stenquist B, Rosdahl I, Ros AM, Synnerstad I, Karlsson M, et al. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol. 2006;86:404–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Serra-Guillen C, Nagore E, Hueso L, Traves V, Messeguer F, Sanmartín O, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5 % versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol. 2012;66:e131–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol. 2003;139:1313–20.PubMedCrossRefGoogle Scholar
  46. 46.
    Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin Dermatol. 2006;24:16–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Patel G, Armstrong A, DB E. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratosis: a systematic review and meta-analysis. JAMA Dermatol. 2014;150:1281–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Gupta A, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169:250–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Martin GM, Stockfleth E. Diclofenac sodium 3 % gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. J Drugs Dermatol. 2012;11:600–8.PubMedGoogle Scholar
  50. 50.
    Maltusch A, Rowert-Huber J, Matthies C, Lange-Asschenfeldt S, Stockfleth E. Modes of action of diclofenac 3 %/hyaluronic acid 2.5 % in the treatment of actinic keratosis. J Dtsch Dermatol Ges. 2011;9:1011–7.PubMedGoogle Scholar
  51. 51.
    Pirard D, Vereecken P, Melot C, Heenen M. Three percent diclofenac in 2.5 % hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005;297:185–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3 % diclofenac sodium gel and 5 % 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156–9.PubMedGoogle Scholar
  53. 53.
    Heller EH, Shiffman NJ. Synthetic retinoids in dermatology. Can Med Assoc J. 1985;132:1129–36.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Thorne EG. Long-term clinical experience with a topical retinoid. Br J Dermatol. 1992;127:31–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132:1583–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1:327–48.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Kang S, Goldfarb MT, Weiss JS, Metz RD, Hamilton TA, Voorhees JJ, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol. 2003;49:83–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Ostertag JU, Quaedvlieg PJ, van der Geer S, Nelemans P, Christianen ME, Neumann MH, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med. 2006;38:731–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch R, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006;142:976–82.PubMedGoogle Scholar
  60. 60.
    Coleman III WP, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg. 1996;22:17–21.PubMedGoogle Scholar
  61. 61.
    Rendon MI, Berson DS, Cohen JL, Roberts WE, Starker I, Wang B. Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. J Clin Aesthet Dermatol. 2010;3:32–43.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Monheit GD. The Jessner’s-trichloroacetic acid peel. An enhanced medium-depth chemical peel. Dermatol Clin. 1995;13:277–83.PubMedCrossRefGoogle Scholar
  63. 63.
    Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz Jr PD. A comparison of the efficacy and safety of Jessner’s solution and 35 % trichloroacetic acid vs 5 % fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176–81.PubMedCrossRefGoogle Scholar
  64. 64.
    Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner’s solution and 35 % trichloroacetic acid vs 5 % fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191–6.PubMedGoogle Scholar
  65. 65.
    Balkrishnan R, Cayce KA, Kulkarni AS, Orsagh T, Gallagher JR, Richmond D, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat. 2006;17:162–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Tierney EP, Eide MJ, Jacobsen G, Ozog D. Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther. 2008;10:81–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Shannon Famenini
    • 1
  • Nason Azizi
    • 2
  • Andy Liu
    • 3
  • Anne Lynn S. Chang
    • 2
    Email author
  1. 1.David Getier School of MedicineLos AngelesUSA
  2. 2.Department of DermatologyStanford University School of MedicineRedwood CityUSA
  3. 3.Albert Einstein College of MedicineBronxUSA

Personalised recommendations